Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 8/20 | 0.44 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19423620 | 0.86 | USP2 (0.51) | USP2GAATSHRMEN1KMT2A | |
| SCHEMBL7465795 | 0.82 | L3MBTL1 (0.56) | USP2GAATSHRMEN1KMT2A | |
| SCHEMBL279853 | 0.80 | USP2 (0.46) | USP2GAATSHRMEN1KMT2A | |
| SCHEMBL5672049 | 0.78 | PARP1 (0.62) | USP2GAATSHRMEN1KMT2A | |
| SCHEMBL13812526 | 0.76 | USP2 (0.44) | USP2GAATSHRMEN1KMT2A | |
| SCHEMBL30674762 | 0.76 | USP2 (0.44) | USP2GAATSHRMEN1KMT2A | |
| SCHEMBL7468823 | 0.75 | BRD4 (0.45) | USP2GAATSHRMEN1KMT2A | |
| SCHEMBL3293755 | 0.74 | BRD4 (0.60) | USP2GAATSHRMEN1KMT2A | |
| SCHEMBL23571859 | 0.74 | USP2 (0.65) | USP2GAATSHRMEN1KMT2A | |
| SCHEMBL29823082 | 0.74 | USP2 (0.65) | USP2GAATSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8134013-B2 | Amide compound and thrombopoietin receptor activator | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-03-13 | — | — | US | disclosed |
| US-20090131659-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131659-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | TEK, PTAFR, MPL | USP2 3755/4885GAA 2220/4885TSHR 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.